The latest quarterly results from the US consumer health products sector come with changes in th4 executive suites for Church & Dwight Co. Inc., Perrigo Co PLC and Prestige Consumer Healthcare Inc.
US Q4 Consumer Health Earnings Preview: Executive, ‘Playbook’ And ‘Fundamental’ Changes
Industry’s results from October-December period start on 22 January with Procter & Gamble reporting its fiscal year 2025 second-quarter numbers and Abbott with its 2024 full-year and fourth-quarter information.
More from Earnings
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
• By
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
More from HBW Insight
• By
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
• By
Tariffs on imports from China and look at eliminating self-affirmed GRAS pathway introduced under Trump while DoJ Consumer Protection Branch also continues supplement sector priorities enduring across administrations.
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.